Xinghua Song

Dr. Xinghua Song


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2023 in International Journal of Surgery
Verified
Journal Article
Open access
YRYouLiang Ren
YouLiang Ren
Lei LiuLei Liu
Lei Liu
DSDong Sun
Dong Sun
ZZZhengdong Zhang
Zhengdong Zhang
MLMeng Li
Meng Li
CXChao Xie
Chao Xie
Background: Post-traumatic related limb osteomyelitis (PTRLO) is a complex bone infection. Currently, there are no available microbial data on a national scale that can guide appropriate antibiotic selection, and explore the dynamic changes in dominant pathogens over time. This study aimed to conduct a comprehensive epidemiological analysis of PTRLO in China. Methods: The study was approved by the Institutional Research Board (IRB), and 3526 PTRLO patients were identified from 212 394 traumatic limb fracture patients at 21 hospitals between 1 January 2008 and 31 December 2017. A retrospective analysis was conducted to investigate the epidemiology of PTRLO, including changes in infection rate (IR), pathogens, infection risk factors and antibiotic resistance and sensitivity. Results: The IR of PTRLO increased gradually from 0.93 to 2.16% (Z=14.392, P<0.001). Monomicrobial infection (82.6%) was significantly higher than polymicrobial infection (17.4%) (P0.05). The most prevalent GP strains were Methicillin-sensitive Staphylococcus aureus (MSSA) (17.03%), Methicillin-resistant Staphylococcus aureus (MRSA) (10.46%), E. faecalis (5.19%) and S. epidermidis (4.87%). In contrast, the dominant strains GN strains were Pseudomonas Aeruginosa (10.92%), E. cloacae (10.34%), E. coli (9.47%), Acinetobacter Baumannii (7.92%) and Klebsiella Pneumoniae (3.33%). In general, the high-risk factors for polymicrobial infection include opened-fracture (odds ratio, 2.223), hypoproteinemia (odds ratio, 2.328), and multiple fractures (odds ratio, 1.465). It is important to note that the antibiotics resistance and sensitivity analysis of the pathogens may be influenced by complications or comorbidities. Conclusions: This study provides the latest data of PTRLO in China and offers trustworthy guidelines for clinical practice. (China Clinical Trials.gov number, ChiCTR1800017597).

7 January 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
YGYuling Gan
Yuling Gan
QLQiuzhen Liang
Qiuzhen Liang
XSXinghua Song
Xinghua Song

5 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
QCQian Chen
Qian Chen
JCJiangtao Chen
Jiangtao Chen
YLYuqing Li
Yuqing Li
DLDawei Liu
Dawei Liu
ZYZeng Yan
Zeng Yan
YYYan Yuan
Yan Yuan
Significance: A viral etiology of osteosarcoma was proposed previously but has never been proven by identifying any virus authentically associated with human osteosarcoma. The current study revealed an association of human osteosarcoma with KSHV infection in osteosarcoma patients of Xinjiang subgroups. First, this study provides evidence that supports a viral etiology of some human osteosarcomas. The gene expression profiling study showed that KSHV-positive osteosarcoma represents a distinct subtype of osteosarcoma which is of diagnostic, prognostic, and therapeutic significance. Second, KSHV-associated osteosarcomas occur preferentially in children and young adults, predicting that KSHV-positive children in KSHV-endemic regions may be at significant risk for osteosarcoma. Third, these findings extend the range of human cancers associated with viruses.

22 November 2023 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
HLHaopeng Luan
Haopeng Luan
CPCong Peng
Cong Peng
KLKai Liu
Kai Liu
XSXinghua Song
Xinghua Song
Objective: To compare the efficacy and safety of unilateral biportal endoscopic transforaminal lumbar interbody fusion (BE-TLIF) and minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) in lumbar degenerative diseases. Methods: This study was registered on International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42023432460). We searched PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wan Fang Database, and Wei Pu Database by computer to collect controlled clinical studies on the efficacy and safety of unilateral BE-TLIF and MIS-TLIF in lumbar degenerative diseases from database establishment to May 2023. Two researchers screened the literature, extracted data and evaluated the risk of bias of the included studies, recorded the authors, and sample size, and extracted the intraoperative blood loss, operation time, postoperative drainage, Oswestry disability index, Visual analogue scale, lumbar lordosis, disk height, hospital length stay, fusion rate, and complications in each study. Meta-analysis was performed using Revman 5.4 software provided by Cochrane Library. Results: A total of 14 cohort studies with a total of 1007 patients were included in this study, including 472 patients in the BE-TLIF group and 535 patients in the MIS-TLIF group. The BE-TLIF group had lower intraoperative blood loss than the MIS-TLIF group [mean difference (MD) = − 78.72, 95% CI (− 98.47, − 58.97), P < 0.00001] and significantly reduced postoperative drainage than the MIS-TLIF group [MD = − 43.20, 95% CI (− 56.57, − 29.83), P < 0.00001], and the operation time was longer than that of the MIS-TLIF group [MD = 22.68, 95% CI (12.03, 33.33), P < 0.0001]. Hospital length stay in BE-TLIF group was significantly less than that in MIS-TLIF group [MD = − 1.20, 95% CI (− 1.82, − 0.57), P = 0.0002]. Conclusion: Compared with MIS-TLIF, BE-TLIF for lumbar degenerative diseases has the advantages of less intraoperative blood loss, less early postoperative low back and leg pain, shorter postoperative hospital length stay, and faster early functional recovery.

1 March 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HLHaopeng Luan
Haopeng Luan
CPCong Peng
Cong Peng
PYParhat Yasin
Parhat Yasin
QSQisong Shang
Qisong Shang
WXWei Xiang
Wei Xiang
XSXinghua Song
Xinghua Song
Background: Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), remains one of the leading causes of death among infectious diseases. Enhancing the ability of anti-tuberculosis drugs to eradicate Mycobacterium tuberculosis within host cells remains a significant challenge. Methods: A mannosamine-modified nanoparticle delivery system was developed using poly(lactic-co-glycolic acid) (PLGA) copolymers to enhance the targeted delivery of rifapentine (RPT) to macrophages. D-mannosamine was conjugated to PLGA-polyethylene glycol (PLGA-PEG) copolymers through EDC/NHS coupling chemistry, and the resultant RPT-MAN-PLGA-PEG nanoparticles (NPs) were prepared through a combination of phacoemulsification and solvent evaporation methods. The physicochemical properties, toxicity, in vitro drug release profiles, stability, cellular uptake, and anti-TB efficacy of the NPs were systematically evaluated. Results: The RPT-MAN-PLGA-PEG NPs had a mean particle size of 108.2 ± 7.2 nm, with encapsulation efficiency and drug loading rates of 81.2 ± 6.3% and 13.7 ± 0.7%, respectively. RPT release from the NPs was sustained for over 60 hours. Notably, the phagocytic uptake of the MAN-PLGA NPs by macrophages was significantly higher compared to PLGA-PEG NPs. Both NPs improved pharmacokinetic parameters without inducing significant organ toxicity. The minimum inhibitory concentration for the NPs was 0.047 μg/mL, compared to 0.2 μg/mL for free RPT. Conclusion: The engineered RPT-MAN-PLGA-PEG NPs effectively enhanced macrophage uptake in vitro and facilitated the intracellular clearance of Mtb. This nanoparticle-based delivery system offers a promising approach for improving the precision of anti-TB therapy, extending drug release, optimizing pharmacokinetic profiles, augmenting antimicrobial efficacy, and mitigating drug-related toxicities.

6 February 2014 in European Spine Journal
Verified
Journal Article
Closed access
PDF file
YZYijun Zhou
Yijun Zhou
LXLeilei Xu
Leilei Xu
XSXinghua Song
Xinghua Song
LDLiwen Ding
Liwen Ding
JCJiangtao Chen
Jiangtao Chen
QLQiuzhen Liang
Qiuzhen Liang